Navigation Links
BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
Date:8/22/2011

RALEIGH, N.C., Aug. 22, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced that the commercial launch and availability of ONSOLIS (fentanyl buccal soluble film) in Canada will take place this quarter.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

ONSOLIS is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL) for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  ONSOLIS will be marketed in Canada by Meda Valeant Pharma Canada Inc., a joint venture between BDSI's commercial partner for ONSOLIS, Meda, and Valeant Canada Limited.  

"We are excited about the upcoming commercial launch of ONSOLIS in Canada," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI.  "The achievement of this important milestone provides an opportunity for growth of ONSOLIS outside of the U.S. market, particularly where commercial efforts will not be impacted by a REMS requirement."

Dr. Sirgo continued, "The Canadian market is also of particular importance as ONSOLIS will be among the first products available for the management of breakthrough pain in opioid tolerant individuals with cancer in that country.  We remain highly confident based on the attributes of ONSOLIS that we can effectively compete in any market and believe that our partner Meda Valeant will leverage these attributes to build an important new market for ONSOLIS in Canada.  We also look forward to introducing ONSOLIS into additional markets in the future."

Valeant Pharmaceuticals International, Inc. is a multi-national specialty pharmaceutical company that develops and markets prescription and nonprescription pharmaceutical products.  In Canada, the Valeant portfolio includes products for the treatment of pain and oncology supportive care, making them an ideal partner for the commercialization of ONSOLIS.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL) for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron).  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release, the presentation described herein and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, those relating to the sales performance of ONSOLIS in Canada) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
2. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
3. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
5. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
6. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
7. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
8. SeraCare Life Sciences Expands Product Portfolio
9. Trinity Pharma Solutions Brings SaaS Benefits to Life Sciences Industry with Rapid Access to Actionable Sales Intelligence
10. HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
11. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... May 23, 2016 Gamida Cell, ... treatment of cancer and orphan genetic diseases, announced today ... $4.4 million from the Israel Innovation Authority (formerly the ... of Economy and Industry. The mission of the Israel ... various industries, including science and technology, while stimulating economic ...
(Date:5/20/2016)... 20, 2016 The Biotech arena ... that the industry is not far from recovering. There ... featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ... ATHX ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... ). Sign up for your free trading alerts on ...
(Date:5/19/2016)... PARIS , May 19,2016 ... Activities at Digestive Disease Week Meeting and 91 ... Society Mauna Kea Technologies (Euronext: MKEA, ... laser endomicroscopy platform, today announced that its Cellvizio ... meeting focused on gastroenterology during the month of ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... Mental health watchdog ... Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its protest ... An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit follows ...
(Date:5/24/2016)... , ... May 24, 2016 , ... Boyd Industries, a ... Delivery Unit® (CDU), a groundbreaking new product for pediatric dentistry , at AAPD ... in San Antonio, TX May 26-29. The Concealed Delivery Unit keeps dental hand pieces ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... May 24, 2016 , ... As reported by MassGeneral.org, on May ... transplant in the United States . The 64-year-old patient who received the transplant had ... could restore not only a natural appearance, but also urinary and sexual function for ...
(Date:5/24/2016)... ... May 24, 2016 , ... Harvard Health Publications, the consumer ... will deliver a new series of Q&A videos to clinicians and patients at ... expertise of Harvard Medical School faculty into brief videos that clinicians using vidscrip ...
Breaking Medicine News(10 mins):